Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
about
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysisDarbepoetin for the anaemia of chronic kidney diseaseRecombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patientsA combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validationSix persistent research misconceptionsErythropoietin and diabetes mellitusEvidence for the prevention and treatment of stroke in dialysis patientsThe optimum hematocrit.Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study).The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease.Regeneration in the nervous system with erythropoietinIncreased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease.Charting a course for erythropoietin in traumatic brain injury.Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice.Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.Anaemia management and mortality risk in chronic kidney disease.Therapy of anemia: is it only a number to reach or are there other variables to control?Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure.Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.Erythropoietin Attenuates Cardiac Dysfunction in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Diabetic Cardiomyopathy.Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients.The role of iron, omega-3 Fatty acids, and vitamins in heart failure.How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?Anemia and mortality in patients with nondialysis-dependent chronic kidney disease.
P2860
Q24187413-30839587-3CBA-4630-9107-3E4F42A21B12Q24197780-AA6FCA89-7D68-4C62-9219-4EAA78159492Q24246372-5408C964-55E9-41D3-8A72-EE543EC0AF0DQ24289291-492AF173-30CD-4CD8-92FD-E2D06150D23AQ24289462-4913BB20-FA40-4713-BFCF-2ECC9F1DAE91Q26777878-011EBFD2-BD31-4A6D-8B3F-4E5D24D287ECQ27023274-467C18EB-9231-458A-BD9B-F1CA69443D76Q34679370-B279E32F-3291-419D-AC31-8A390CD40258Q35944877-AECE1097-7E13-4982-A6A1-819DC6BE72CFQ36012626-643A54CA-D0BD-4AB7-90DD-EF1C364D174BQ36073903-7E58CB60-FBD6-4FC7-90BD-1364EFCDD7F6Q36247651-87FE0C3B-F2C4-455E-AAB5-66C6D0D6B5A4Q36436893-3F8C2321-B969-498E-81EE-D3F3A66F1F5DQ36791150-DD5348A9-74C9-4402-8A3B-CB5D4AACBF0DQ37046746-8B5BD29D-7126-4C37-ADD1-85F4BBD034B3Q38037120-CFE049D6-F075-4CC9-98AE-A0689BF17BA6Q38084470-5F437750-CB16-4955-9644-6D1BCA8EC7C2Q38111881-2EF1C847-664A-4A3C-B8D9-5B15F19FA919Q38229636-0847D6ED-EEBC-4328-A50D-F2D5B43A90A4Q38281535-259C9125-CED0-400B-90B4-7FF6B0183844Q38740871-46FA60AE-7E30-4245-BDD0-E9F42D837EF9Q38826645-0AE2BF5A-B2CD-487E-815F-C8712B72313FQ42241135-02870AEF-E4FA-451C-ADE2-E194E49C03D5Q44963037-D7934E7F-D70C-463A-BBF6-87974E778959Q45012876-9508862C-E895-4545-BDFE-69DF39F6C4BCQ47988307-27D2F42A-C7C1-4AF8-A4B0-C0E1203DBC10Q48338113-1E93D6C3-4BDB-40F1-BABA-C833CDBE59BAQ49141144-32681120-6CD5-4979-838C-59DEADE4262DQ50910928-497A9EC6-8E5E-40E7-8FC2-463CB5448622Q51318153-EDB7F695-CA36-4909-9A65-8FE270C82581Q53096541-3CA2E136-3F54-4164-A856-C6788D524DACQ55360137-79B003B3-D9C0-4FF6-8AEA-23778B8E9167
P2860
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Stroke in patients with type 2 ...... sp therapy (TREAT) experience.
@en
type
label
Stroke in patients with type 2 ...... sp therapy (TREAT) experience.
@en
prefLabel
Stroke in patients with type 2 ...... sp therapy (TREAT) experience.
@en
P2093
P50
P1433
P1476
Stroke in patients with type 2 ...... esp therapy (TREAT) experience
@en
P2093
Ajay K Singh
Eldrin F Lewis
Hajime Uno
Hans-Henrik Parving
Janet B McGill
Marc A Pfeffer
Patrick S Parfrey
Peter Ivanovich
Sai Ram Keithi-Reddy
Scott D Solomon
P304
P356
10.1161/CIRCULATIONAHA.111.030411
P407
P577
2011-11-21T00:00:00Z